Skip to main content

Table 2 PSC patients and controls enrolled in the previous protocol (IRB #670-02)

From: The PSC scientific community resource: an asset for multi-omics interrogation of primary sclerosing cholangitis

Variable

PSC patients

Controls

n

1174

650

Age (yrs)a, median (IQR)

51.6 (36.6–61.6)

61.3 (53.9–68.1)

Sex, n (%) male

733 (62.4)

177 (27.2)

Race, n (%) Caucasian

1087 (92.6)

646 (99.4)

Available Specimens, n (%) of participants [total # of aliquots]

Genomic DNA / BC

1166 (99.3) [3,316]

624 (96.0) [1,723]

Plasma

1117 (95.1) [5,821]

635 (97.7) [2,100]

Serum

719 (61.2) [1,705]

540 (83.1) [1,229]

PBMC

1091 (92.9) [2,743]

607 (93.4) [1,120]

Stool

95 (8.1) [185]

not collected

Age at PSC dx (yrs), median (IQR)

40.6 (29.0-52.1)

na

PSC duration (yrs)a, median (IQR)

6.2 (2.3–12.9)

na

IBD Type, n (%) of patients

Ulcerative colitis

728 (62.4)

na

Crohn’s Disease

119 (10.2)

Indeterminate IBD

54 (4.6)

No IBD

266 (22.8)

Status unknown

7

Clinical follow-upb, n (%) of patients

None

564 (48.0)

na

0–3 Years

180 (15.3)

3–6 Years

207 (17.6)

6 + Years

223 (19.0)

Liver Transplant, n (%) of patients

Prior to enrollment

243 (20.7)

na

In follow-up

74 (6.3)

No transplant

857 (73.0)

Advanced Diseasec, n (%) of patients

Prior to enrollment

366 (31.2)

na

In follow-up

107 (9.1)

No advanced disease

701 (59.7)

Hepatobiliary Cancerd, n (%) of patients

Prior to enrollment

76 (6.5)

na

In follow-up

50 (4.3)

No hepatobiliary cancer

1048 (89.3)

  1. na, not applicable; BC, buffy coat; PBMC, peripheral blood mononuclear cells; IBD, inflammatory bowel disease
  2. aAt time of blood sample collection
  3. bClinical follow-up post first blood sample collection performed under IRB#670-02
  4. cAdvanced disease defined as having one or more of the following: liver transplant, cirrhosis determination or hepatic decompensation event
  5. dHepatobiliary cancer defined as having one or more of the following: cholangiocarcinoma, hepatocellular carcinoma or gallbladder cancer